Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBIT (2020 - 2022)

Atea Pharmaceuticals has reported EBIT over the past 3 years, most recently at -$39.9 million for Q4 2022.

  • Quarterly results put EBIT at -$39.9 million for Q4 2022, down 132.93% from a year ago — trailing twelve months through Dec 2022 was -$130.6 million (down 194.42% YoY), and the annual figure for FY2025 was -$180.9 million, up 6.25%.
  • EBIT for Q4 2022 was -$39.9 million at Atea Pharmaceuticals, down from -$16.3 million in the prior quarter.
  • Over the last five years, EBIT for AVIR hit a ceiling of $121.2 million in Q4 2021 and a floor of -$42.2 million in Q1 2022.
  • Median EBIT over the past 3 years was -$13.1 million (2020), compared with a mean of -$275333.3.
  • Biggest five-year swings in EBIT: surged 857.85% in 2021 and later tumbled 471.76% in 2022.
  • Atea Pharmaceuticals' EBIT stood at $20.6 million in 2020, then skyrocketed by 486.92% to $121.2 million in 2021, then plummeted by 132.93% to -$39.9 million in 2022.
  • The last three reported values for EBIT were -$39.9 million (Q4 2022), -$16.3 million (Q3 2022), and -$32.3 million (Q2 2022) per Business Quant data.